BrightPath Biotherapeutics

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel cancer immunotherapies to transform the treatment of refractory or progressive cancers that are untreatable with traditional standard therapies. BrightPath Biotherapeutics is actively involved in developing cell therapies, immune-modulating antibodies, and new drugs targeting cancer-specific neoantigens that are currently undergoing clinical trials.